胰脂肪酶（Pancrelipases），特别是它的缓释剂型(例如： Creon, Pancreaze, Pertzye, Ultresa, Zenpep) 是猪源性胰淀粉酶的商用混合物(作用于淀粉水解酶)，胰脂肪酶和胰凝乳蛋白酶（一种蛋白酶），其治疗目的是为了给那些没有足够胰腺酶的婴儿、小孩、成人在食物消化上的改善，因为它们会影响胰腺，如囊性纤维化、慢性胰腺炎或在胰腺和肠之间的信道堵塞等作用。这产品中的三个组成部分是类似那些通常由人类胰腺产生的消化酶。长期的胰腺酶替代产品（PERPs），有一些甚至使用了一个多世纪，2006年美国食品药品管理局要求制药公司提交猪源性PERP产品的保密合约；Creon®（AbbVie公司）是最早的美国食品药品管理局指令后，批准商业PERP产品的公司，在2009年正式在市场上市。

Pancrelipases are commercial mixtures of pig-derived pancreatic amylase (a hydrolase acting on starch), pancreatic lipase, and chymotrypsin (a protease). They are used to improve food digestion in people who do not have enough pancreatic enzymes due to chronic pancreatitis, cystic fibrosis or obstruction of the pancreatic duct. The three components in the product are digestive enzymes akin to those normally produced by the human pancreas. Longstanding pancreatic enzyme replacement products (PERPs)—some in use for a century or more—fell under a 2006 FDA requirement that pharmaceutical companies with porcine-derived PERP products submit an NDA for each; Creon® (AbbVie Inc.) was the first of the commercial PERP products approved after the FDA directive, reaching market in 2009.